Genmab A/S (GNMSF) Stock Price, News & Analysis

Company Overview

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Key Stats

• Today's Range: $213.88 to $217.40
• 50-Day Range: $198.00 to $231.93
• 52-Week Range: $192.20 to $323.02
• Volume: 4,785 shs
• Average Volume: 1,849 shs
• Market Capitalization: $14.20 billion
• P/E Ratio: 20.66
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GNMSF Stock Analysis - Frequently Asked Questions

How have GNMSF shares performed this year?

Genmab A/S's stock was trading at $207.38 at the beginning of 2025. Since then, GNMSF shares have increased by 3.6% and is now trading at $214.8920.
View the best growth stocks for 2025 here.

How were Genmab A/S's earnings last quarter?

Genmab A/S (OTCMKTS:GNMSF) released its earnings results on Wednesday, November, 5th. The company reported $0.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.45 by $0.02. The company earned $45.65 million during the quarter, compared to analysts' expectations of $53.94 million. Genmab A/S had a net margin of 23.49% and a trailing twelve-month return on equity of 17.73%.

How do I buy shares of Genmab A/S?

Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 11/05/2014
• Today: 1/21/2025
• Next Earnings (Estimated): 2/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:GNMSF
• CUSIP: N/A
• CIK: 1434265
• Web: www.genmab.com
• Phone: (457) 020-2728
• Fax: 45-7020-2729
• Employees: 2,204
• Year Founded: 1999

Profitability

• EPS (Most Recent Fiscal Year): $10.40
• Trailing P/E Ratio: 20.66
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $631.91 million
• Net Margins: 23.49%
• Pretax Margin: 32.75%
• Return on Equity: 17.73%
• Return on Assets: 14.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.17
• Quick Ratio: 5.15

Sales & Book Value

• Annual Sales: $2.39 billion
• Price / Sales: 5.94
• Cash Flow: $12.84 per share
• Price / Cash Flow: 16.73
• Book Value: $69.46 per share
• Price / Book: 3.09

Miscellaneous

• Outstanding Shares: 66,070,000
• Free Float: 65,057,000
• Market Cap: $14.20 billion
• Optionable: Not Optionable
• Beta: 1.04